Fig. 1.All targets of thymosin-1 and COVID-19 were identified
and the shared targets of thymosin-1 treating COVID-19 for drawing the
PPI network. COVID-19, Corona Virus Disease 2019; PPI, protein-protein
interaction; CASP8, Caspase 8; UBE2I, Ubiquitin Conjugating Enzyme E2 I; HLA-A,
Histocompatibility Complex, Class I, A; ANPEP, Alanyl Aminopeptidase; PRKCE,
Protein Kinase C Epsilon; CASP3, Caspase 3; CASP6, Caspase 6; ACE, Angiotensin I
Converting Enzyme; CTSB, Cathepsin B; CTSL, Cathepsin L; MAPK8, Mitogen-Activated
Protein Kinase 8; FURIN, Paired Basic Amino Acid Cleaving Enzyme; NOS2, Nitric
Oxide Synthase 2; DPP4, Dipeptidyl Peptidase 4; PTGS2, Prostaglandin-Endoperoxide
Synthase 2; F10, Coagulation Factor X; HLA-DRB1, Major Histocompatibility
Complex, Class II, DR Beta 1; F11, Coagulation Factor XI; ADAM17, ADAM
Metallopeptidase Domain 17. CASP8; UBE21; HLA-A; ANPEP; PRKCE; CASP3; CASP6; ACE; CTSB; CTSL; MAPK8;
FURIN; NOS2; DPP4; PTGS2; F10; HLA-DRB1; F11; ADAM17.